Cresset Asset Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $15.3M | Buy |
634,638
+7,943
| +1% | +$208K | 0.06% | 206 |
|
|
2026
Q1 | $17.6M | Sell |
626,695
-29,860
| -5% | -$795K | 0.08% | 173 |
|
|
2025
Q4 | $16.3M | Sell |
656,555
-12,630
| -2% | -$318K | 0.07% | 179 |
|
|
2025
Q3 | $17.1M | Buy |
669,185
+19,427
| +3% | +$479K | 0.07% | 159 |
|
|
2025
Q2 | $15.8M | Buy |
649,758
+175,339
| +37% | +$4.09M | 0.08% | 156 |
|
|
2025
Q1 | $12M | Buy |
474,419
+76,743
| +19% | +$2.01M | 0.06% | 197 |
|
|
2024
Q4 | $10.6M | Sell |
397,676
-569,887
| -59% | -$15.5M | 0.05% | 220 |
|
|
2024
Q3 | $28M | Buy |
967,563
+47,469
| +5% | +$1.38M | 0.11% | 125 |
|
|
2024
Q2 | $25.7M | Buy |
920,094
+294,145
| +47% | +$8.1M | 0.11% | 125 |
|
|
2024
Q1 | $17.4M | Buy |
625,949
+146,091
| +30% | +$4.05M | 0.08% | 164 |
|
|
2023
Q4 | $13.8M | Sell |
479,858
-74,822
| -13% | -$2.26M | 0.08% | 167 |
|
|
2023
Q3 | $18.4M | Sell |
554,680
-42,870
| -7% | -$1.52M | 0.07% | 135 |
|
|
2023
Q2 | $21.9M | Buy |
597,550
+373,377
| +167% | +$14.5M | 0.03% | 173 |
|
|
2023
Q1 | $9.15M | Buy |
224,173
+6,407
| +3% | +$277K | 0.18% | 83 |
|
|
2022
Q4 | $8.5M | Sell |
217,766
-12,681
| -6% | -$608K | 0.11% | 86 |
|
|
2022
Q3 | $10.1M | Sell |
230,447
-2,221
| -1% | -$108K | 0.13% | 74 |
|
|
2022
Q2 | $12M | Sell |
232,668
-1,070
| -0.5% | -$54.5K | 0.15% | 67 |
|
|
2022
Q1 | $12.1M | Sell |
233,738
-56,173
| -19% | -$2.91M | 0.13% | 73 |
|
|
2021
Q4 | $17.1M | Buy |
289,911
+41,412
| +17% | +$2.05M | 0.17% | 62 |
|
|
2021
Q3 | $10.7M | Buy |
248,499
+10,172
| +4% | +$451K | 0.14% | 57 |
|
|
2021
Q2 | $9.33M | Buy |
238,327
+21,891
| +10% | +$851K | 0.13% | 59 |
|
|
2021
Q1 | $7.84M | Sell |
216,436
-89,728
| -29% | -$3.19M | 0.12% | 66 |
|
|
2020
Q4 | $11.3M | Sell |
306,164
-21,307
| -7% | -$782K | 0.18% | 48 |
|
|
2020
Q3 | $11.4M | Buy |
327,471
+11,466
| +4% | +$402K | 0.21% | 48 |
|
|
2020
Q2 | $9.8M | Buy |
316,005
+88,939
| +39% | +$3.02M | 0.22% | 47 |
|
|
2020
Q1 | $7.03M | Buy |
227,066
+94,648
| +71% | +$3.23M | 0.21% | 41 |
|
|
2019
Q4 | $4.92M | Buy |
132,418
+23,441
| +22% | +$835K | 0.13% | 67 |
|
|
2019
Q3 | $3.71M | Buy |
108,977
+8,981
| +9% | +$327K | 0.11% | 84 |
|
|
2019
Q2 | $4.11M | Buy |
99,996
+52,506
| +111% | +$2.08M | 0.13% | 82 |
|
|
2019
Q1 | $1.91M | Buy |
47,490
+13,306
| +39% | +$533K | 0.07% | 70 |
|
|
2018
Q4 | $1.42M | Buy |
+34,184
| New | +$1.42M | 0.08% | 54 |
|
Other funds holding PFE
Cresset Asset Management's PFE Position: Q2 2026 in Review
Cresset Asset Management increased its Pfizer (PFE) stake by 1.3% in Q2 2026, buying an estimated $208K and bringing the position to 634,638 shares worth $15.3M. The position accounts for 0.06% of the portfolio, ranked #206.
Cresset Asset Management first reported a position in PFE in Q4 2018 and has held it in 31 quarters since. The position peaked at $28M in Q3 2024. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Cresset Asset Management held 634,638 shares of Pfizer worth $15.3M as of Q2 2026.
- Cresset Asset Management bought 7,943 Pfizer shares in Q2 2026, an estimated $208K.
- Pfizer made up 0.06% of Cresset Asset Management's portfolio in Q2 2026, its #206 holding.
- Cresset Asset Management first reported a position in Pfizer in Q4 2018 and has held it in 31 quarters since.
- Cresset Asset Management's Pfizer position peaked at $28M in Q3 2024.
- 2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Cresset Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.